$TEVA

Hughes Eric A sold $892K of TEVA

Hughes Eric A (See "Remarks") sold 25,578 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.88 ($0.89M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hughes Eric A
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider activity but does not include new fundamentals, guidance, litigation, or operational changes.

02

Market read

Traders may note insider selling, but the 10b5-1 structure makes it a low-conviction catalyst.

03

What to watch

Insider sales can be routine for diversification or tax planning; without additional context (e.g., option exercises, other concurrent filings), directional inference is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

SEC Form 4 insider transaction for TEVA, reported as an open-market sale by an officer under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

TEVA insider Form 4 shows Hughes Eric A sold 25,578 shares at $34.8757 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and outweighed by the plan structure.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive value versus unscheduled sales.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity-driven and not a bearish signal, especially given the pre-arranged 10b5-1 plan.

Key entities

  • TEVA PHARMACEUTICAL INDUSTRIES LTD

    Subject of the Form 4 insider sale disclosure.

  • Hughes Eric A

    Officer who sold 25,578 shares at $34.8757 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEVAMedAI 8/10

Medincell’s Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026

Teva presented new data on Olanzapine LAI and UZEDY® at Psych Congress 2026. Olanzapine LAI, in Phase 3 trials, showed 56% stabilization and 4% relapse rate among stabilized participants. UZEDY® data indicated better treatment continuity and lower healthcare costs. Olanzapine LAI awaits FDA decision in Q4 2026. Both treatments use Medincell's BEPO® technology.

$TEVAMed

World Data Showing UZEDY (risperidone) Outperforms Other Long

Teva Pharmaceuticals presented real-world data showing UZEDY (risperidone) outperforms other treatments in schizophrenia, reducing emergency care and healthcare costs. The study found UZEDY patients had fewer ED visits and hospitalizations, with $1,036.70 monthly savings per patient. Teva highlighted UZEDY's role in improving treatment continuity and lowering healthcare resource utilization.